Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8485 |
Intermediate Similarity |
NPD4749 |
Approved |
0.8456 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.8444 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8382 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.837 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8333 |
Intermediate Similarity |
NPD1613 |
Approved |
0.8333 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8248 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.8195 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.8175 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.8169 |
Intermediate Similarity |
NPD6099 |
Approved |
0.8169 |
Intermediate Similarity |
NPD6100 |
Approved |
0.8102 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.8077 |
Intermediate Similarity |
NPD6671 |
Approved |
0.8058 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.803 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.8029 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.8015 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7908 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7714 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7703 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7697 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7652 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7613 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7569 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7569 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7554 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7554 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7536 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.75 |
Intermediate Similarity |
NPD228 |
Approved |
0.7482 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7481 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.7481 |
Intermediate Similarity |
NPD7340 |
Approved |
0.747 |
Intermediate Similarity |
NPD7549 |
Discontinued |
0.7452 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7451 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7448 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7439 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7434 |
Intermediate Similarity |
NPD1511 |
Approved |
0.74 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7391 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7389 |
Intermediate Similarity |
NPD37 |
Approved |
0.7388 |
Intermediate Similarity |
NPD1398 |
Phase 1 |
0.7385 |
Intermediate Similarity |
NPD968 |
Approved |
0.7376 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7375 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7358 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7358 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7358 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7357 |
Intermediate Similarity |
NPD2230 |
Approved |
0.7357 |
Intermediate Similarity |
NPD2233 |
Approved |
0.7357 |
Intermediate Similarity |
NPD2232 |
Approved |
0.7351 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7338 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7338 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7329 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.7329 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7324 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7305 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7301 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7297 |
Intermediate Similarity |
NPD6111 |
Discontinued |
0.7296 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7286 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7286 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7285 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.7285 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7279 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7279 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7279 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7279 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7266 |
Intermediate Similarity |
NPD289 |
Clinical (unspecified phase) |
0.7256 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7256 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7256 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7255 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.725 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.725 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7241 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7239 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7237 |
Intermediate Similarity |
NPD3750 |
Approved |
0.723 |
Intermediate Similarity |
NPD4097 |
Suspended |
0.7212 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7211 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7197 |
Intermediate Similarity |
NPD290 |
Approved |
0.7197 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7192 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.719 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7188 |
Intermediate Similarity |
NPD2560 |
Approved |
0.7188 |
Intermediate Similarity |
NPD2563 |
Approved |
0.7183 |
Intermediate Similarity |
NPD5327 |
Phase 3 |
0.7169 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7161 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7161 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7153 |
Intermediate Similarity |
NPD4624 |
Approved |
0.7152 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7152 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7152 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7152 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7152 |
Intermediate Similarity |
NPD4675 |
Approved |
0.7143 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7143 |
Intermediate Similarity |
NPD1778 |
Approved |
0.7133 |
Intermediate Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.7133 |
Intermediate Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.7126 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7125 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7124 |
Intermediate Similarity |
NPD6331 |
Phase 2 |
0.7124 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7124 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7118 |
Intermediate Similarity |
NPD4577 |
Approved |
0.7118 |
Intermediate Similarity |
NPD4578 |
Approved |
0.7114 |
Intermediate Similarity |
NPD6353 |
Approved |
0.7113 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7105 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7099 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7097 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.7097 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.7095 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7093 |
Intermediate Similarity |
NPD4663 |
Approved |
0.7091 |
Intermediate Similarity |
NPD2969 |
Approved |
0.7091 |
Intermediate Similarity |
NPD2970 |
Approved |
0.709 |
Intermediate Similarity |
NPD3022 |
Approved |
0.709 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7086 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7083 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7083 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7081 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7078 |
Intermediate Similarity |
NPD2677 |
Approved |
0.7077 |
Intermediate Similarity |
NPD940 |
Approved |
0.7077 |
Intermediate Similarity |
NPD846 |
Approved |
0.7075 |
Intermediate Similarity |
NPD3268 |
Approved |
0.7071 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7071 |
Intermediate Similarity |
NPD5585 |
Approved |
0.7066 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7063 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7059 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD7635 |
Approved |
0.7052 |
Intermediate Similarity |
NPD7906 |
Approved |
0.7051 |
Intermediate Similarity |
NPD4160 |
Clinical (unspecified phase) |
0.7051 |
Intermediate Similarity |
NPD1754 |
Clinical (unspecified phase) |
0.7048 |
Intermediate Similarity |
NPD27 |
Approved |
0.7048 |
Intermediate Similarity |
NPD2489 |
Approved |
0.7042 |
Intermediate Similarity |
NPD1611 |
Approved |
0.7039 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7039 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7034 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.703 |
Intermediate Similarity |
NPD6071 |
Discontinued |
0.703 |
Intermediate Similarity |
NPD3051 |
Approved |
0.702 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7018 |
Intermediate Similarity |
NPD7312 |
Approved |
0.7018 |
Intermediate Similarity |
NPD7313 |
Approved |
0.7018 |
Intermediate Similarity |
NPD7310 |
Approved |
0.7018 |
Intermediate Similarity |
NPD7311 |
Approved |
0.7013 |
Intermediate Similarity |
NPD7466 |
Approved |
0.7006 |
Intermediate Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.7006 |
Intermediate Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.6993 |
Remote Similarity |
NPD2231 |
Phase 2 |
0.6993 |
Remote Similarity |
NPD2235 |
Phase 2 |
0.6977 |
Remote Similarity |
NPD8053 |
Approved |
0.6977 |
Remote Similarity |
NPD7309 |
Approved |
0.6977 |
Remote Similarity |
NPD8054 |
Approved |
0.6974 |
Remote Similarity |
NPD2796 |
Approved |
0.697 |
Remote Similarity |
NPD8127 |
Discontinued |
0.6959 |
Remote Similarity |
NPD7808 |
Phase 3 |
0.6957 |
Remote Similarity |
NPD3382 |
Approved |
0.6957 |
Remote Similarity |
NPD3383 |
Approved |
0.6957 |
Remote Similarity |
NPD3384 |
Approved |
0.6954 |
Remote Similarity |
NPD2200 |
Suspended |
0.6943 |
Remote Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.6941 |
Remote Similarity |
NPD6797 |
Phase 2 |
0.6937 |
Remote Similarity |
NPD4380 |
Phase 2 |
0.6934 |
Remote Similarity |
NPD7843 |
Approved |
0.6933 |
Remote Similarity |
NPD3657 |
Discovery |
0.6933 |
Remote Similarity |
NPD447 |
Suspended |
0.6928 |
Remote Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.6928 |
Remote Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.6928 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6914 |
Remote Similarity |
NPD5929 |
Approved |
0.6914 |
Remote Similarity |
NPD7819 |
Suspended |
0.6908 |
Remote Similarity |
NPD3748 |
Approved |
0.6908 |
Remote Similarity |
NPD1510 |
Phase 2 |
0.6901 |
Remote Similarity |
NPD7251 |
Discontinued |
0.6901 |
Remote Similarity |
NPD4626 |
Approved |
0.6901 |
Remote Similarity |
NPD17 |
Approved |
0.6897 |
Remote Similarity |
NPD3225 |
Approved |
0.6894 |
Remote Similarity |
NPD6072 |
Discontinued |
0.689 |
Remote Similarity |
NPD7833 |
Phase 2 |
0.689 |
Remote Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.689 |
Remote Similarity |
NPD4055 |
Discovery |
0.689 |
Remote Similarity |
NPD7832 |
Clinical (unspecified phase) |
0.689 |
Remote Similarity |
NPD7831 |
Phase 2 |
0.6883 |
Remote Similarity |
NPD1549 |
Phase 2 |
0.6879 |
Remote Similarity |
NPD4357 |
Discontinued |
0.6879 |
Remote Similarity |
NPD7837 |
Clinical (unspecified phase) |
0.6879 |
Remote Similarity |
NPD7741 |
Discontinued |
0.6879 |
Remote Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.6875 |
Remote Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.6871 |
Remote Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.6871
|
Remote Similarity |
NPD1712 |
Approved |